PanTher Therapeutics
Austin, US · Founded 2014 · Delaware corporation · 18 employees on LinkedIn · 4 known investors
Find your way into PanTher Therapeutics
Sign up to see every warm intro you have to PanTher Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the PanTher Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
PanTher develops targeted cancer therapeutics that deliver drugs directly to tumor sites at high concentrations over extended periods, aiming to improve clinical outcomes while reducing side effects. The platform is designed to be applicable across multiple therapeutic types for oncology treatment.
Founders & leadership
PanTher Therapeutics was founded in 2014 by Laura Indolfi and Elazer Edelman.

Board



Investors · 4
How we know: the company's own site · Catalyst Health Ventures's portfolio page · funding news · Not right? Tell us
How we know: Angel Physicians Fund's portfolio page · a partner's Signal profile · Not right? Tell us
How we know: Mission Biocapital's portfolio page · funding news · the VCSheet dataset · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
Funding
SEC filings, press & company announcements$21.4M disclosed across 10 of 11 rounds · 2015–2025
- $5.4MSeries AJun 2021 · 2 sourcesSource ↗
▶$3MraisedApr 2025 · 26 investors · BiotechnologyRule 506(b)
- Laura IndolfiExecutive Officer, Director
- D MackeyDirector
- Daniel WildmanDirector
- Darshana ZaveriDirector
- Maria PalasisDirector
- Offering amount
- $5M
- Amount sold
- $3M
- First sale
- Mar 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.7MraisedDec 2023 · 28 investors · BiotechnologyRule 506(b)
- John EdwardsDirector
- Daniel WildmanDirector
- Laura IndolfiExecutive Officer, Director
- Manish BhandariDirector
- Maria PalasisDirector
- Darshana ZaveriDirector
- Offering amount
- $5M
- Amount sold
- $2.7M
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.3MraisedDec 2022 · 15 investors · BiotechnologyRule 506(b)
- Laura IndolfiExecutive Officer, Director
- Maria PalasisDirector
- David TingDirector
- Darshana ZaveriDirector
- Manish BhandariDirector
- Offering amount
- $2M
- Amount sold
- $1.3M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.1MraisedJun 2022 · 17 investors · Other Health CareRule 506(b)
- DARSHANA ZAVERIDirector
- MARIA PALASISDirector
- MANISH BHANDARIDirector
- LAURA INDOLFIExecutive Officer, Director
- DAVID TINGDirector
- Offering amount
- $1.2M
- Amount sold
- $1.1M
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.3MraisedJun 2021 · 59 investors · Other Health CareRule 506(b)
- Maria PalasisDirector
- Manish BhandariDirector
- David TingDirector
- Laura IndolfiExecutive Officer, Director
- Darshana ZaveriDirector
- Offering amount
- $7.3M
- Amount sold
- $7.3M
- First sale
- May 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$209.5KraisedMay 2020 · 15 investors · Other Health CareRule 506(b)
- David TingDirector
- Laura IndolfiExecutive Officer, Director
- Elazer EdelmanDirector
- Offering amount
- $209.5K
- Amount sold
- $209.5K
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$268.1KraisedMay 2020 · 6 investors · Other Health CareRule 506(b)
- Elazer EdelmanDirector
- Laura IndolfiExecutive Officer, Director
- David TingDirector
- Offering amount
- $268.1K
- Amount sold
- $268.1K
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$35KraisedNov 2016 · 1 investors · Other Health CareRule 506(b)
- Elazer EdelmanDirector
- David TingDirector
- Laura IndolfiExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $35K
- First sale
- Oct 2016
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as PanTher Therapeutics.
Frequently asked questions
- What does PanTher Therapeutics do?
- PanTher develops targeted cancer therapeutics that deliver drugs directly to tumor sites at high concentrations over extended periods, aiming to improve clinical outcomes while reducing side effects. The platform is designed to be applicable across multiple therapeutic types for oncology treatment.
- Who founded PanTher Therapeutics?
- PanTher Therapeutics was founded by Laura Indolfi, Elazer Edelman in 2014.
- Who are PanTher Therapeutics's investors?
- PanTher Therapeutics's investors include Catalyst Health Ventures, Angel Physicians Fund, Mission Biocapital, Walnut Venture Associates.
- How much funding has PanTher Therapeutics raised?
- PanTher Therapeutics has disclosed $21.4M raised across 10 of its 11 known rounds.
- Where is PanTher Therapeutics headquartered?
- PanTher Therapeutics is headquartered in Austin, US.



